Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 762349, 14 pages
http://dx.doi.org/10.1155/2015/762349
Research Article

Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension

1Department of Rheumatology, Peking Union Medical College Hospital, Beijing 100032, China
2State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
3Department of Cardiology, Peking Union Medical College Hospital, Beijing 100730, China

Received 9 October 2014; Accepted 21 December 2014

Academic Editor: James C. C. Wei

Copyright © 2015 Shuang Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Rubin, “Primary pulmonary hypertension,” The New England Journal of Medicine, vol. 336, no. 2, pp. 111–117, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Distler and A. Pignone, “Pulmonary arterial hypertension and rheumatic diseases—from diagnosis to treatment,” Rheumatology, vol. 45, no. 4, pp. iv22–iv25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. F. M. Wigley, J. A. C. Lima, M. Mayes, D. McLain, J. L. Chapin, and C. Ward-Able, “The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER Study),” Arthritis and Rheumatism, vol. 52, no. 7, pp. 2125–2132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Puri, M. D. McGoon, and S. S. Kushwaha, “Pulmonary arterial hypertension: current therapeutic strategies,” Nature Clinical Practice Cardiovascular Medicine, vol. 4, no. 6, pp. 319–329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. J. Rubin, D. B. Badesch, R. J. Barst et al., “Bosentan therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 346, no. 12, pp. 896–903, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Galiè, A. L. Hinderliter, A. Torbicki et al., “Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 41, no. 8, pp. 1380–1386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Prasad, J. Wilkinson, and M. A. Gatzoulis, “Sildenafil in primary pulmonary hypertension,” New England Journal of Medicine, vol. 343, no. 18, article 1342, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. E. D. Michelakis, W. Tymchak, M. Noga et al., “Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension,” Circulation, vol. 108, no. 17, pp. 2066–2069, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. B. K. S. Sastry, C. Narasimhan, N. K. Reddy, and B. S. Raju, “Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study,” Journal of the American College of Cardiology, vol. 43, no. 7, pp. 1149–1153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Galiè, H. A. Ghofrani, A. Torbicki et al., “Sildenafil citrate therapy for pulmonary arterial hypertension,” New England Journal of Medicine, vol. 353, no. 20, pp. 2148–2157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. M. Hoeper, M. Schwarze, S. Ehlerding et al., “Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue,” New England Journal of Medicine, vol. 342, no. 25, pp. 1866–1870, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Galiè, M. Humbert, J.-L. Vachiéry et al., “Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial,” Journal of the American College of Cardiology, vol. 39, no. 9, pp. 1496–1502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Barst, M. McGoon, V. McLaughlin et al., “Beraprost therapy for pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 41, no. 12, pp. 2119–2125, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. L. Archer and E. D. Michelakis, “An evidence-based approach to the management of pulmonary arterial hypertension,” Current Opinion in Cardiology, vol. 21, no. 4, pp. 385–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Csiszar, N. Labinskyy, S. Olson et al., “Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats,” Hypertension, vol. 54, no. 3, pp. 668–675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Guignabert, B. Raffestin, R. Benferhat et al., “Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats,” Circulation, vol. 111, no. 21, pp. 2812–2819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. T. Schermuly, E. Dony, H. A. Ghofrani et al., “Reversal of experimental pulmonary hypertension by PDGF inhibition,” Journal of Clinical Investigation, vol. 115, no. 10, pp. 2811–2821, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Dumitrascu, N. Weissmann, H. A. Ghofrani et al., “Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling,” Circulation, vol. 113, no. 2, pp. 286–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Labinskyy, A. Csiszar, G. Veress et al., “Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen,” Current Medicinal Chemistry, vol. 13, no. 9, pp. 989–996, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Ungvari, Z. Orosz, A. Rivera et al., “Resveratrol increases vascular oxidative stress resistance,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 292, no. 5, pp. H2417–H2424, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, and Z. Ungvari, “Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 4, pp. H1694–H1699, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. K. J. Pearson, J. A. Baur, K. N. Lewis et al., “Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span,” Cell Metabolism, vol. 8, no. 2, pp. 157–168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Nakayama, T. Yaguchi, S. Yoshiya, and T. Nishizaki, “Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner,” Rheumatology International, vol. 32, no. 1, pp. 151–157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. N. Feige and J. Auwerx, “Transcriptional targets of sirtuins in the coordination of mammalian physiology,” Current Opinion in Cell Biology, vol. 20, no. 3, pp. 303–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Potente and S. Dimmeler, “Emerging roles of SIRT1 in vascular endothelial homeostasis,” Cell Cycle, vol. 7, no. 14, pp. 2117–2122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. J. Zhang, Z. Wang, H. Z. Chen et al., “Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice,” Cardiovascular Research, vol. 80, no. 2, pp. 191–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Stein, C. Lohmann, N. Schäfer et al., “SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis,” European Heart Journal, vol. 31, no. 18, pp. 2301–2309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Zhou, H.-Z. Chen, Y.-Z. Wan et al., “Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction,” Circulation Research, vol. 109, no. 6, pp. 639–648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Li, H. N. Zhang, H. Z. Chen et al., “SIRT1 acts as a modulator of neointima formation following vascular injury in mice,” Circulation Research, vol. 108, no. 10, pp. 1180–1189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Izikki, C. Guignabert, E. Fadel et al., “Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents,” Journal of Clinical Investigation, vol. 119, no. 3, pp. 512–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Lee and S. K. Moon, “Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells,” Journal of Nutrition, vol. 135, no. 12, pp. 2767–2773, 2005. View at Google Scholar · View at Scopus
  32. R. Zhang, H.-Z. Chen, J.-J. Liu et al., “SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages,” Journal of Biological Chemistry, vol. 285, no. 10, pp. 7097–7110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-M. Li and G. Brooks, “Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system. Potential targets for therapy?” European Heart Journal, vol. 20, no. 6, pp. 406–420, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Li, Z. Li, X. Sun et al., “Heme oxygenase-1/p21WAF1 mediates peroxisome proliferator-activated receptor-γ signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells,” The FEBS Journal, vol. 277, no. 6, pp. 1543–1550, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Ma, L. J. Stafford, D. li et al., “GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis,” Journal of Cellular Biochemistry, vol. 100, no. 6, pp. 1376–1386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Zhu, Q. Liu, M. Wang et al., “Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts,” PloS ONE, vol. 6, no. 11, Article ID e27081, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. S. J. Lee and M. M. Kim, “Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells,” Life Sciences, vol. 88, no. 11-12, pp. 465–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Niederer, C. Ospelt, F. Brentano et al., “SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance,” Annals of the Rheumatic Diseases, vol. 70, no. 10, pp. 1866–1873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K. T. Howitz, K. J. Bitterman, H. Y. Cohen et al., “Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan,” Nature, vol. 425, no. 6954, pp. 191–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. M. L. Paffett, S. N. Lucas, and M. J. Campen, “Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle,” Vascular Pharmacology, vol. 56, no. 1-2, pp. 64–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Thirunavukkarasu, S. V. Penumathsa, S. Koneru et al., “Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase,” Free Radical Biology and Medicine, vol. 43, no. 5, pp. 720–729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. I. Lekli, G. Szabo, B. Juhasz et al., “Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 294, no. 2, pp. H859–H866, 2008. View at Google Scholar
  44. S. V. Penumathsa, S. Koneru, S. M. Samuel et al., “Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor,” Free Radical Biology and Medicine, vol. 45, no. 7, pp. 1027–1034, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Kanno, Y. J. L. Wu, P. C. Lee, T. R. Billiar, and C. Ho, “Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats,” Circulation, vol. 104, no. 8, pp. 945–950, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. D. W. Stacey, “Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells,” Current Opinion in Cell Biology, vol. 15, no. 2, pp. 158–163, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. S. C. Slater, E. Koutsouki, C. L. Jackson et al., “R-cadherin: beta-catenin complex and its association with vascular smooth muscle cell proliferation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1204–1210, 2004. View at Publisher · View at Google Scholar · View at Scopus